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Abstract
We investigated two siblings with granulomatous histiocytosis prominent in the nasal area, mimicking rhinoscleroma and
Rosai-Dorfman syndrome. Genome-wide linkage analysis and whole-exome sequencing identified a homozygous frameshift
deletion in SLC29A3, which encodes human equilibrative nucleoside transporter-3 (hENT3). Germline mutations in SLC29A3
have been reported in rare patients with a wide range of overlapping clinical features and inherited disorders including H
syndrome, pigmented hypertrichosis with insulin-dependent diabetes, and Faisalabad histiocytosis. With the exception of
insulin-dependent diabetes and mild finger and toe contractures in one sibling, the two patients with nasal granulomatous
histiocytosis studied here displayed none of the many SLC29A3-associated phenotypes. This mild clinical phenotype
probably results from a remarkable genetic mechanism. The SLC29A3 frameshift deletion prevents the expression of the
normally coding transcripts. It instead leads to the translation, expression, and function of an otherwise noncoding, out-of-
frame mRNA splice variant lacking exon 3 that is eliminated by nonsense-mediated mRNA decay (NMD) in healthy
individuals. The mutated isoform differs from the wild-type hENT3 by the modification of 20 residues in exon 2 and the
removal of another 28 amino acids in exon 3, which include the second transmembrane domain. As a result, this new
isoform displays some functional activity. This mechanism probably accounts for the narrow and mild clinical phenotype of
the patients. This study highlights the ‘rescue’ role played by a normally noncoding mRNA splice variant of SLC29A3,
uncovering a new mechanism by which frameshift mutations can be hypomorphic.
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Introduction
Rhinoscleroma (RS) is a chronic, granulomatous disease of the
upper respiratory tract caused by the bacteria Klebsiella rhinoscler-
omatis. Migration from an area in which RS is endemic (such as
North Africa or Central America) appears to be an important
factor in disease development, consistent with infection occurring
during childhood [1]. However, RS is rare and it is possible that
only a small fraction of infected individuals develop the disease,
suggesting that RS may also result from host predisposition due to
an inherited or acquired immunodeficiency [1]. The recent
discoveries of genetic etiologies of infectious diseases of childhood
as diverse as tuberculosis [2], herpes simplex encephalitis [3],
invasive pneumococcal disease [4], and chronic mucocutaneous
candidiasis [5,6] suggest that single-gene inborn errors of
immunity may also underlie other life-threatening infectious
diseases of childhood, including RS [7,8]. We describe here the
investigation of two patients born to a consanguineous family from
Morocco (Figure 1A). Both patients were originally diagnosed with
RS (individuals 7 and 8, family VII in [1]) at the ages of 5 and 14
years, with no overt acquired immunodeficiency. We therefore
hypothesized that RS may segregate as an autosomal recessive
trait in this kindred.
Results
Case reports
Two siblings were originally diagnosed with RS on the basis of
nasal obstruction, epistaxis, a granulomatous appearance of the
nasal mucosa and radiological and histological analyses [1].
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29708However, important new data were recently obtained, leading to a
revision of this diagnosis, as explained below.
The older brother, P1 (Figure 1A, B), is the first child of first-
cousin parents of Moroccan origin. He was born at term, with
normal health indicators and metrics, following an uneventful
pregnancy. P1 has an adult height of 162 cm, which is close to
167 cm, his predicted adult height based on the heights of his
parents (his father is 168 cm tall and his mother is 155 cm tall). He
was diagnosed with insulin-dependent diabetes at the age of 5
years. He was subsequently diagnosed with exocrine pancreas
insufficiency at the age of 9 years, following the observation of
bulky stools and steatorrhea with levels of fat in stool at 12 g/
24 hr. At this stage, a diagnosis of cystic fibrosis was excluded and
a computed tomography (CT) scan of the pancreas was normal. At
the age of 14 years, nasal obstruction occurred, with infiltrates
found in both the nose and the right maxillary sinus (Figure 1C).
P1 was then diagnosed with RS. Several operations were required
to free the nasal fossae, between the ages of 14 and 18 years. An
improvement was observed after the initiation of antibiotic
treatment, but multiple relapses occurred 10 months after
treatment, despite the use of various combinations of antibiotics.
Apparently spontaneous recovery was observed from the age of 18
years onwards. Biological signs of inflammation persisted, with
both a high erythrocyte sedimentation rate (.50 mm) and poly-
clonal hypergammaglobulinemia (IgG=15.3 g/l, IgA=4.2 g/l,
IgM=2.8 g/l). Finally, P1 developed a very mild contracture of
the fingers and toes at the age of 12 years (Figure 1D). At last
follow up, the patient was 33 years old and had insulin-dependent
diabetes and exocrine pancreatic deficiency. He is doing well, with
daily subcutaneous insulin and oral pancreatic extract treatments,
which have normalized his glycemia and steatorrhea. He has
required no further surgery since the age of 18 years, but still
suffers from chronic nasal obstruction and an enlarged nose due to
the presence of a nasal mass (Figure 1B). He recently suffered from
local pain of the knee. X-ray revealed lytic bone lesions of both
patellas (Figure 1E). No other lesions were detected on X-ray or
bone scintigraphy. This patient is otherwise healthy (Table 1).
Both cardiac morphology and function were normal on cardiac
ultrasonography (US). Dermatologist examination revealed no
pigmented hypertrichotic skin lesions and skin biopsies taken at 3
different sites were normal. Speech and tone audiometries were
normal. Ophtalmologic examination revealed mild diabetic
retinopathy but no uveitis and no histiocytic infiltration.
The second patient, P2 (Figure 1A, B), is the fourth and
youngest sibling in the family. At the age of five years, she
developed a nasal obstruction and epistaxis (Figure 1F). Her
condition initially seemed to improve on antibiotic treatment, but
she had relapses at the ages of six and seven years, necessitating
surgery to free the nasal fossae. Like her brother, she displayed
chronic inflammation, with a high erythrocyte sedimentation rate
Figure 1. Clinical and radiological data of the patients P1 and P2. (A) Pedigree of the family. Squares: male subjects; circles: female subjects;
closed symbols: affected individuals; open symbols: unaffected individuals; double horizontal line: consanguineous marriage. (B) Both patients suffer
from chronic nasal obstruction, with enlarged noses. (C–E) Clinical phenotypes of P1. (C) CT scan of the sinuses showing a nasal mass. (D) Mild finger
contractures with campodactyly. (E) Lytic lesions of both patellae. (F–H) Clinical phenotype of P2. (F) CT scan of the sinuses showing a nasal mass. (G)
Abdominal CT scan with retroperitoneal fibrosis. (H) No hand abnormalities.
doi:10.1371/journal.pone.0029708.g001
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(IgG=16.2 g/l, IgA=5.1 g/l, IgM=3.1 g/l). At the age of 17
years, she presented with retroperitoneal fibrosis (Figure 1G). At
her last follow up, the patient was 23 years old with an adult height
of 162 cm. She did not display any signs of insulin-dependent
diabetes or exocrine pancreatic deficiency and is otherwise healthy
(Figure 1H and Table 1). Both cardiac morphology and function
were normal on cardiac US. Dermatologist examination revealed
no pigmented hypertrichotic skin lesions. Speech and tone
audiometries were normal. Ophtalmologic examination was
normal with no uveitis and no histiocytic infiltration. All these
clinical results and the comparisons with patients reported with
mutations in SLC29A3 are reported in Table 1.
Histological and microbiological features
RS was diagnosed partly on the basis of the histological findings
for the two patients. Slides of several biopsy specimens were
recently reviewed, with additional immunohistochemical analysis.
For P1, specimens from nasal cavity biopsies performed at the ages
of 18 and 30 years were available for histological review. On the
first biopsy, the mucosa displayed fibrosis and a mild to moderate
inflammatory infiltrate containing plasma cells, lymphocytes and
some vacuolated histiocytes. The histiocytes resembled Mikulicz
cells. However Wartin-Starry, Grocott and periodic acid-Schiff
(PAS) stains were negative. The nasal biopsy specimen obtained at
the age of 30 years also contained areas with vacuolated histiocytes
and numerous plasma cells (Figure 2A). In addition, other parts of
the biopsy specimens also displayed specific features of Rosai-
Dorfman histiocytosis, as they contained several large histiocytes
with emperipolesis. These histiocytes were positive for CD68, CD4
and S100 protein (Figure 2B). P1 also underwent resection of a
large (2 cm diameter) subcutaneous nodule of the right arm at the
age of 19 years. This nodule was well circumscribed and localized
within the deep dermis and hypodermis. A diagnosis of Rosai-
Dorfman histiocytosis was clear, based on the presence of several
large S100 protein-positive histiocytes with emperipolesis
(Figure 2C–D). Most of the cells contained within macrophages
were CD4 lymphocytes. Mononucleated vacuolated and spumous
macrophages were also abundant (Figure 2E).
For P2, nasal cavity biopsies performed at the age of 12 years
disclosed histological lesions similar to those of the second nasal
sample from P1, typical of Rosai-Dorfman histiocytosis. The
histiocytes with emperipolesis were positive for CD68, CD4 and
S100 protein (Figure 2F). CD1a and factor XIIIa staining were not
conclusive, probably due to the use of Bouin fixation. A biopsy
specimen from the area of retroperitoneal fibrosis displayed
fibrosis and the presence of a few mononucleated cells, but no
vacuolated or spumous histiocytes or emperipolesis.
In summary, the nasal cavity biopsy specimens of both siblings
presented histological lesions of chronic inflammation, with
fibrosis, large numbers of plasma cells and vacuolated histiocytes
mimicking Mikulicz cells. However, some nasal biopsy specimens
and one skin nodule also contained large S100 protein-positive
histiocytes with lymphocyte emperipolesis typical of Rosai-Dorf-
man histiocytosis. It should also be stressed that bacterial cultures
of Klebsiella Rhinoscleromatis in the nasal biopsy specimens from both
patients were negative.
Genome-wide linkage and whole-exome sequencing
We searched for morbid lesions by combining genome-wide
linkage (GWL) analysis by homozygosity mapping and whole-
exome sequencing (WES) by next-generation deep sequencing
Table 1. Clinical phenotype of the patients and patients already reported in the literature with SLC29A3 mutations.
P1 P2 H syndrome PHID FHC SHML Mild SLC29A3 disorder
Nasal infiltration ++ 22 ++ 2
Hyperpigmentation 22 ++ 22 2
Hypertrichosis 22 ++ 22 2
Sensorineural deafness 22 + 2 ++ +
Hepatomegaly 22 ++ 2 + 2
Short stature 22 ++ + + 2
Hypogonadism 22 + 2 + 22
Gynecomastia 22 + 222 2
Delayed puberty 22 2 + 22 2
Pancreatic exocrine deficiency + 22 + 22 2
Insulin-dependent diabetes + 22 + 22 2
Uveitis 22 + 2 ++ 2
Hallux valgus 22 + 222 2
Contractures of the fingers + 2 + 2 + 22
Contractures of the toes + 2 + 2 + 22
Contracture of the ankle 22 2 2 + 22
Myelofibrosis 22 + 22+ 2
Retroperitoneal fibrosis 2 + 22 2 2 2
Lymphadenopathy 22 2 +++ +
Heart anomalies 22 + 222 2
References this report this report 19 16 20 20 23
doi:10.1371/journal.pone.0029708.t001
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the first human patients with FADD deficiency in a kindred with
bacterial and viral infections [11], and in deciphering the cause of
nonsyndromic hearing loss DFNB82 [12]. For the linkage analysis,
we genotyped the two affected patients (P1 and P2) and their
parents (I.1 and I.2) (Figure 3A) with the Affymetrix 6.0 array.
Seven regions (.1 Mb) were homozygous in the two affected
patients and heterozygous in other members of the family
(Table 2). In parallel, WES of P1 was performed using the Agilent
SureSelect Human All Exon 38 Mb kit. We identified a total of
17,687 coding variations after alignment and variant calling. We
identified 177 coding or splicing variants in the linked regions
(Table S1). Only two of these variants were novel, not being
reported in the NCBI dbSNP 134, in the data from the first 1,094
genomes sequenced from the 1000 Genomes Project (June 2011
data release on http://www.1000genomes.org) [13] (Table 2), or
our in-house database (composed of more than 200 exomes from
patients with different clinical phenotypes). The two variants
mapped to the chromosome 10 linkage region. The first is a
homozygous deletion of 1 nucleotide, c.241-243delA (referred to
hereafter as c.243delA), in exon 2 of SLC29A3 (NM_018344.5,
MIM 612373) (Figure 3B, C), leading to a frameshift starting at
amino acid 81, p.K81Nfs (referred to hereafter as 81fs). The
second variant identified is a homozygous c.610G.C mutation in
exon 5 of VCL (NM_003373.3, MIM 193065), leading to the
amino acid change valine to leucine at amino acid position 204,
p.V204L. We validated these variants by Sanger sequencing on
genomic DNA from peripheral blood and on cDNA from Epstein-
Barr virus-transformed B cells (EBV-B cells).
Identification of c.243delA in SLC29A3 as the disease-
causing mutation
The two variants identified by WES were considered as
potentially disease-causing. However, in silico analysis with
PolyPhen2 [14] predicted that the c.610G.C variant in VCL
would be benign. We also checked the mRNA levels of VCL in the
Figure 2. Histology of nasal (A, B, F) and skin (C, D, E) biopsy specimens from P1 (A–E) and P2 (F). Most biopsy specimens contained
vacuolated histiocytes suggestive of Mikulicz cells (A, E). Some specimens also contained large S100 protein-positive histiocytes enclosing
lymphocytes (emperipolesis) (B, C, D, F). H&E staining (A, C, E) and immunohistochemical staining for S100 protein (B, D, F). Original magnification
6200 (A) and 6400 (B–F).
doi:10.1371/journal.pone.0029708.g002
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control cells (data not shown). Finally mutations in VCL have been
linked to hypertrophic cardiomyopathy [15], a condition not
observed in P1 and P2. By contrast, the SLC29A3 variant led to a
frameshift in exon 2 (Figure 3C). In addition to our analyses of the
databases described earlier, we also sequenced 70 healthy
individuals from Morocco. None of these controls presented the
variation, suggesting that it is not an irrelevant polymorphism.
This mutation segregated with the disease status in all family
members (Figure 3A). Interestingly, various disorders due to
SLC29A3 mutations have only recently been documented,
including H syndrome (MIM 612391), pigmented hypertrichosis
with insulin-dependent diabetes mellitus (PHID) syndrome (MIM
612391), Faisalabad histiocytosis (FHC) (MIM 602782) and sinus
histiocytosis with massive lymphadenopathy (SHML), all compris-
ing granulomatous lesions [16,17,18,19,20,21,22,23] (Figure 3C).
Moreover, our patients presented a few of the non-granulomatous
clinical phenotypes previously reported in patients with SLC29A3
mutations, such as insulin-dependent diabetes and finger contrac-
ture for P1 (Table 1). The c.243delA variant in SLC29A3 is
therefore most likely disease-causing in these patients.
c.243delA leads to the expression of a mRNA splice
variant of SLC29A3 that is otherwise noncoding
The SLC29A3 gene comprises six exons and encodes human
equilibrative nucleoside transporter 3 (hENT3). Using the TA
cloning technique to amplify and sequence the full-length cDNA
of SLC29A3 from control EBV-B cells, we identified three different
mRNA variants. Transcript variant 1 (NM_018344.5) encodes a
protein of 475 amino acids and accounted for more than 75% of
the transcripts. Transcript variant 2 (NM_001174098.1) encodes a
protein of 258 amino acids and accounted for less than 5% of
SLC29A3 transcripts. The final transcript variant detected in
control cells was variant 3 (NR_033413.1). Variant 3 is normally a
noncoding RNA, as it skips exon 3 (83 base pairs), leading to a
Table 2. Whole-exome analysis results of P1.
Total
coding
a
Coding in
1kgenomes
Coding in
dbSNP134
Novel
coding
a
Total
splice
a
Novel
splice
a
Total
ncRNA
a
Novel
ncRNA
a
Whole Exome 17,687 15,424 9,999 261 554 13 56 0
Linked regions
Chr.
Start marker –
position
b
End marker –
position
b
Total
coding
Coding in
1kgenomes
Coding in
dbSNP134
Novel
coding
Total
splice
Novel
splice
Total
ncRNA
Novel
ncRNA
1 rs6656194 -
165,765,014
rs12120152 -
171,723,809
3 7 3 7 3 6 0300 0
1 rs6683655 -
188,436,602
rs4329563 -
202,090,641
4 9 4 8 4 8 0400 0
6 rs342658 –
124,035,264
rs2136055 –
130,966,801
1 3 1 3 1 3 0000 0
8 rs2167362 –
34,980,598
rs543864 –
36,995,907
0 0 0 0000 0
10 rs7911065 –
63,030,749
rs4980022 –
80,834,685
61 58 58 2 600 0
12 rs1387760 –
92,177,784
rs2128894 –
94,883,246
4 4 4 0000 0
22 rs6008817 –
46,814,671
rs1884516 –
48,325,524
5 5 5 0000 0
Coding variants include missense, nonsense, frameshift, in-frame deletions and insertions and readthrough variants.
Splice variants include all variants within 8 bp in the intron side, or 3 bp in the exon side of a splice junction.
a: Both homozygous and heterozygous variations are included.
b: Position coordinates for the markers correspond to the hg19, NCBI build 37.
doi:10.1371/journal.pone.0029708.t002
Figure 3. Identification of a frameshift deletion in SLC29A3. (A) Pedigree of the family. The SLC29A3 genotypes of the patients and the family
members from whom DNA was available for sequence analysis are listed under their symbols. Genotyping was carried out twice. (B) Illumina
sequencing reads displayed for patient P1. Reads overlapping the mutation in exon 2 of SLC29A3 (bp position g.73,082,741–g.73,082,765; hg19; NCBI
37) show the homozygous deletion of one A leading to a frameshift (c.243delA). (C) Diagram of SLC29A3. Introns are represented by a straight line. 59-
UTR and 39-UTR are represented by open rectangles. The coding region is represented by closed rectangles. Previously reported mutations are
indicated at the corresponding locations. The mutation identified in P1 and P2 is shown in a red rectangle. (D–E) Abnormal expression of SLC29A3
transcript variants 1, 2 and 3 in the patients’ EBV-B cells. (D) SLC29A3 exons 2–4 were amplified from cDNA obtained from the EBV-B cells of two
controls (Ctrl 1 and Ctrl 2) and two patients (P1 and P2) and were ligated to the pCR2.1 vector. Clones containing SLC29A3 transcripts were
sequenced, and the frequency of each variant was calculated by dividing the number of clones containing the particular transcript by the total
number of sequenced clones. For Ctrl1: variants 1 and 2: 65/81 and variant 3: 16/81. For Ctrl2: variants 1 and 2: 37/44 and variant 3: 7/44. For P1:
variants 1 and 2: 31/85 and variant 3: 54/85. For P2: variants 1 and 2: 20/76 and variant 3: 56/76. Each variant is represented by a diagram, with
numbers indicating the number of the exon. The red vertical line indicates the position of the c.243delA mutation. The closed rectangle below each
transcript variant represents the corresponding translation products. Gray boxes indicate amino acids modified with respect to the WT form. (E)
Levels of SLC29A3 mRNA (variants 1 and 3 combined) were assessed by Q-PCR on EBV-B cells from four healthy controls (Ctrls), two parents (Het.), and
the two patients. Threshold cycles (Ct) for SLC29A3, normalized with respect to those of GUS (DCt), are plotted as 2
2(DCt). Each dot represents the
mean of three independent experiments for each individual. The horizontal bars indicate the mean for all individuals sharing the same genotype.
doi:10.1371/journal.pone.0029708.g003
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position 197 (Figure 3D). The c.243delA frameshift mutation
would lead to a premature termination codon at position 100 in
the two coding mRNA variants (transcript variants 1 and 2). This
mutation would therefore be expected to result in the nonsense-
mediated mRNA decay (NMD) of these variants [24,25].
However, the c.243delA mutation counterbalances the frameshift
induced by the splicing out of exon 3 in variant 3. The
combination of the deletion and the splicing out of exon 3 results
in a loss of 83+1=84 base pairs, which is equivalent to 28
codons. This should result in a return to the correct reading
frame after the first codon of exon 4, and the absence of a
premature termination codon (Figure 3D). We tested this
hypothesis by amplifying cDNA generated from RNA extracted
from EBV-B cells and assessing the proportion of each variant in
cells from controls or from the patients. For each patient and two
healthy controls, we sequenced about 80 clones obtained by TA
cloning. Transcript variant 3 accounted for less than 20% of the
clones obtained from the controls, whereas it accounted for more
than two third of the clones from the patients (Figure 3D). Total
SLC29A3 transcript levels, as assessed by quantitative PCR (Q-
PCR) with a probe binding at the junction of exons 5 and 6 and
recognizing both WT and mutated variants 1 and 3, were similar
in cells from patients and controls (Figure 3E). Thus, the
c.243delA mutation leads to an increase in both the relative
proportion and the absolute quantity of SLC29A3 transcript
variant 3 in the patients’ cells, and induces NMD of transcript
variants 1 and 2. This situation is the opposite of that observed in
cells from healthy controls.
The mutated SLC29A3 transcript variant 3 produces a
stable hENT3 protein isoform with partial nucleoside
transport activity
hENT3 belongs to a group of solute carrier (SLC) transporters
widely conserved in eukaryotes, the ENT or SLC29 family
[26,27]. The four members of the ENT family are passive
transporters, Na
+ independent, and display a broad tissue
distribution [28,29]. hENT3 is a protein with 11 transmembrane
domains, according to in silico predictions by SVMtm (http://ccb.
imb.uq.edu.au/svmtm/) and the TMpred program (http://www.
ch.embnet.org/software/TMPRED_form.html), and analogy with
the topology of hENT1 [26,30], which has a sequence 29%
identical to that of hENT3 (Figure 4A). We hypothesized that the
mutated transcript variant 3 would lead to the expression of a new,
mutated isoform of hENT3 (possible model based on the in silico
predictions of SVMtm or TMpred in Figure S1) and that the loss
of transmembrane domain 2 would have no effect on the stability
of this protein. The amino acid sequences of the mutated proteins
encoded by the different transcript variants are shown in
Supplementary Text S1. No commercial antibodies against
hENT3 gave conclusive results in our hands. We therefore
generated eight constructs carrying SLC29A3 variant 1 WT or
with the c.243delA mutation, variant 3 WT or with the c.243delA
mutation with either a V5 tag at the C-terminus or a Myc tag at
the N-terminus, to test our hypothesis. The transfection of
HEK293T cells with these constructs demonstrated that
hENT3-variant3-81fs was expressed, resulting in levels of protein
similar or slightly lower to those of hENT3-variant1-WT
(Figure 4B and Figure S2). The bands corresponding to hENT3-
variant3-81fs showed that the hENT3-variant3-81fs proteins
migrated slightly more rapidly than the hENT3-variant1-WT,
due to the loss of 28 amino acids in the protein encoded by
mutated variant 3 (Figure 4B). The multiple bands observed are
consistent with findings for previous hENT3 blots on HeLa cells or
diverse tissues [28], and may correspond to oligomers and
precursor or degraded forms of the transporter in addition to
hENT3. We checked that the cells were efficiently transfected, by
carrying out Q-PCR to assess levels of SLC29A3 mRNA
(Figure 4C). We demonstrated that this mutation resulted in the
stable protein expression of an otherwise noncoding splice variant
of SLC29A3.
Two members of the ENT family, hENT1 and hENT2 localize
at the plasma membrane whereas hENT3 was first shown to
localize in the late endosome/lysosome membrane [28] and then
at the mitochondrial membrane [31], all of them significantly
contributing to nucleoside and nucleobase salvage [27]. Moreover,
hENT3 has been reported to be a pH-dependent intracellular
transporter with maximal activity at pH 5.5 [28]. We investigated
the functionality of hENT3-variant3-81fs, by assessing its adeno-
sine transport activity at pH 5.5. As previously described [18], we
first introduced the mutant and WT SLC29A3 sequences into a
Xenopus oocyte expression vector, for the generation of capped
RNAs (cRNA) by in vitro transcription, which we then injected into
Xenopus oocytes, to investigate changes in [
3H] adenosine
transports. We found that hENT3-variant3-81fs presented a
highly decreased adenosine transporter activity compared to
hENT3-variant1-WT (Figure 4D). However, hENT3-variant3-
81fs displayed significant higher levels of transporter activity
compared to hENT3-variant1-81fs or hENT3-variant3-WT, or
even hENT3-variant1-314fs or hENT3-variant1-349fs, two mu-
tants leading to PHID and H syndrome respectively [16,19]
(Figure 4D). These findings may account for the previously
unreported, narrow, and milder clinical phenotype of the patients
than of other patients with SLC29A3 mutations, including
frameshift deletions in particular. Three other frameshift muta-
tions in SLC29A3 have been reported (Figure 3C). However, the
c.307delTT mutation generates an immediate termination codon
[20], and both the c.940delT and c.1045delC mutations are
located in exon 6 [16,19], which encompasses the 39-UTR.
Therefore, our genetic mechanism of interest does not take place
in cells carrying these mutations.
Discussion
Mutations in the SLC29A3 gene have been implicated in various
related syndromes in humans: ‘H syndrome’ [19,21], PHID [16],
FHC and SHML [20]. Some patients may even present a
combination of phenotypes from two or more of these syndromes
[22,32] (Table 1). This led to the suggestion that these phenotypes
should be grouped together as ‘SLC29A3 disorder’ [20]. The
histological features of the lesions seem to be the most uniform
phenotype in these patients. Doviner et al. proposed standardized
criteria useful for diagnosis in a study of the histological features of
skin biopsy specimens from 10 patients with SLC29A3 disorder
[17]. Their analysis revealed the presence of striking mononuclear
infiltrates of monocyte-derived cells, consisting partly of small
CD68
+ histiocytes and of plasma cells. In addition, the small
CD68
+ histiocytes had an unusual distended endoplasmic
reticulum and few lysosomes [17]. We describe here two siblings
with a novel homozygous mutation in SLC29A3 (c.243delA).
Histological analysis of the nasal mucosa lesions of these patients
showed characteristic widespread fibrosis and infiltrates of specific
histiocytes and plasma cells typical of SLC29A3 disorder [17].
Overall, the genetic analysis, the revised histological analyses and
the fact that Klebsiella Rhinoscleromatis culture was negative on
samples from the patients showed that the patients did not display
RS. This correction of diagnosis highlights the value of WES as a
diagnostic tool in patients with rare and complex phenotypes.
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PLoS ONE | www.plosone.org 7 January 2012 | Volume 7 | Issue 1 | e29708Figure 4. Expression and characteristics of hENT3-variant3-81fs. (A) Scheme of hENT3-variant1-WT based on the protein structure predicted
by SVMtm or TMpred programs. Transmembrane domains are represented by long rectangles. The gray and red boxes highlight the amino acids that
are not identical in hENT3-variant1-WT and hENT3-variant3-81fs. In the gray box: amino acids 81–100 that are replaced by 20 other amino acids in
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PLoS ONE | www.plosone.org 8 January 2012 | Volume 7 | Issue 1 | e29708However, these patients had unique sets of clinical manifesta-
tions, different from that of other patients with mutations in
SLC29A3. In particular, they displayed no cutaneous hyperpig-
mentation and the mucocutaneous lesions seemed to be restricted
to the nasal mucosa, resulting in the initial diagnosis of RS. No
hepatosplenomegaly, heart abnormalities, hearing loss or hypo-
gonadism were detected. Thus, P1 and P2 have a mild version of
SLC29A3 disorder. Among the two patients we report, P2 had the
mildest phenotype, not displaying any signs of insulin-dependent
diabetes or exocrine pancreatic deficiency. On the other hand, P2
developed retroperitoneal fibrosis (RF) after 12 years of nasal
infiltration and chronic inflammation. RF has never before been
reported in a patient with SLC29A3 mutation, but was frequently
associated with Erdheim-Chester disease, another rare non-
Langerhans cell histiocytosis of unknown origin [33]. Our findings
expand the genetic and clinical spectra of SLC29A3 disorders and
illustrate how WES could rapidly expand the clinical boundaries of
known genetic defects, as previously illustrated by the discovery of
STIM1 deficiency in a kindred with Kaposi sarcoma (KS), which
revealed both the first genetic etiology of KS and a new phenotype
of STIM1 deficiency [10].
Previous studies on SLC29A3 disorder have shown that the
SLC29A3 genotype alone cannot explain the variability in clinical
presentation. For example, the p.G437R mutation was identified
in patients with H syndrome, PHID, or FHC [16,19,20].
Moreover, two sisters carrying the same SLC29A3 haplotype
(p.G427S/G437R) displayed also two different phenotypes. The
older one had a severe form of both H syndrome and PHID
whereas the younger sister presented with PHID only [22]. This is
consistent with the fact that P1 and P2 do not have exactly the
same clinical phenotype. Yet they both present with phenotypes
much milder than the majority of previously reported patients.
This was unexpected, as no mild phenotype has been observed in
patients with homozygous frameshift or nonsense mutations
[16,19]. The only patient with a mild phenotype had a
homozygous missense mutation (p.R363Q) [23]. Mutations in
VCL or in other genes in the linked regions, or elsewhere in the
genome, might have contributed to the mild clinical phenotype.
An alternative explanation is that, despite the frameshift mutation,
the mutant protein might retain some function in these patients.
Indeed, we showed how this frameshift mutation, which is the
first identified mutation in exon 2 of SLC29A3, is hypomorphic.
This mutation decreases the levels of transcript variant 1 through
NMD and results in an absence of the WT protein, but allows the
expression of a mutated mRNA transcript variant 3, which would
ordinarily be subject to NMD. This hENT3-variant3-81fs variant
was expressed but displayed lower levels of adenosine transporter
activity than the hENT3-variant1-WT protein. This intermediate
level of transporter activity is consistent with the mild phenotype of
the patients, which lies somewhere between those of healthy
individuals and of other patients with more severe SLC29A3
disorders. This is, to our knowledge, the first mutation to be
characterized that leads to the expression of an mRNA variant
that is normally subject to NMD. This new genetic mechanism
may be general and may account for the hypomorphic nature of
some frameshift mutations in other genes, those located towards
the 59 end of a gene in particular. Usually it is thought that mRNA
variants carrying premature stop codons due to alternative splicing
and, thus, subject to NMD are involved in gene regulation [34,35].
We provide here an example of mRNA splice variants playing a
‘rescue’ role, leading to the production of a functional protein.
This study highlights a potential new ‘rescue’ role for noncoding
mRNA splice variants.
Materials and Methods
Ethics statement
This study was conducted in accordance with the principles of
the Declaration of Helsinki. The study was approved by the
Rockefeller Institutional Review Board (IRB approval number:
2010-A00650-39). All patients provided written informed consent
for the collection of samples and subsequent analysis, and for the
publication of pictures.
Whole-genome linkage analysis
We genotyped the two patients (P1 and P2) and their parents
(I.1 and I.2) with the Affymetrix genome-wide SNP array 6.0
(Affymetrix, Santa Clara, CA) comprising 909,622 SNPs, at the
Rockefeller University Genomics Resource Center. Genotyping
was highly successful, with call rates of 98 to 99% across study
subjects. Only autosomal chromosome SNPs with a 100% call rate
and a minor allele frequency (MAF) .0.25 among parents were
retained, and no Mendelian errors were allowed, leaving 342,565
high-quality SNPs for linkage analysis. Genome-wide homozygos-
ity mapping was performed using MERLIN [36], under a
recessive model, with penetrance set to 0.9 and no allowance for
sporadic cases. Multipoint LOD scores were obtained at each
position, and regions longer than 1 Mb in length attaining the
maximum LOD score of 1.8 for the family were defined as priority
regions for the screening of exome sequencing data.
Whole-exome sequencing
Exome capture was performed with the Agilent SureSelect
Human All Exon 38 Mb kit (Agilent Technologies). Single-end
sequencing was performed on an Illumina Genome Analyzer IIx
(Illumina) generating 72-base reads. We aligned the sequences
with the hg19 reference build of the human genome, using the
Burrows-Wheeler Aligner [37]. Downstream processing and
variant calling were carried out with the Genome Analysis Toolkit
(GATK) [38], Samtools [39] and Picard tools (http://picard.
sourceforge.net). Substitution and indel calls were made with
GATK Unified Genotyper. All calls with read coverage ƒ46and
a phred-scaled SNP quality of 30 were filtered out. Variants were
annotated with GATK GenomicAnnotator.
Sanger sequencing of genomic DNA
Genomic DNA was isolated from the peripheral blood
mononuclear cells of the patients and members of their family.
The 59-GCTCTCCAACCAGGCTTTGG-39 and 59-CTGGAA-
ATGTGTCTGAAATCTC-39 primers were used to sequence
SLC29A3 exon 2 and its flanking intron regions.
hENT3-variant3-81fs. In the red box: amino acids 101–128 that are deleted in hENT3-variant3-81fs. (B) Levels of hENT3 proteins were assessed by
immunoblotting with an anti-V5-tag antibody. The V5 tag was located at the C-terminus of hENT3. (C) The graph shows the relative SLC29A3 mRNA
levels measured by Q-PCR for the same experiment with the V5-tagged constructs. Threshold cycles (Ct) for SLC29A3, normalized with respect to
those of GUS (DCt), are plotted as 2
2(DCt). Immunoblotting and Q-PCR results representative of three independent experiments are shown. (D)
Adenosine transport activity. Uptake of [
3H]adenosine (0.026 mM) in Xenopus oocytes 48 h after the injection of D36hENT3-variant1-WT or other
variants with or without the 81fs mutation as well as one H (349fs) and one PHID syndrome (314fs) mutant cRNAs. pH-dependent uptake at pH 5.5.
The data shown are the means 6 SEM from three independent experiments.
*, p,0.05,
***, p,0.001.
doi:10.1371/journal.pone.0029708.g004
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Total RNA from EBV-B cells was used to generate cDNA with
the SuperScript III First-Strand Synthesis System (Invitrogen).
SLC29A3 expression was assessed using the TaqMan gene
expression assay: Hs00983219_m1*, which binds to the exon 5–6
boundary. VCL expression was assessed using the TaqMan gene
expression assay: Hs00419715_m1. The results obtained were
normalized as a function of GUS (b-glucuronidase) gene expression.
Analysis of the different SLC29A3 transcripts
Full-length SLC29A3 cDNA was amplified from the EBV-B cells
of patients and controls with the 59-CACCGACATGGC-
CGTTGTCTCAGAGG-39 and 59-GATGAGGTGCACCAG-
GAGGGTAGA-39 primers. SLC29A3 exons 2–4 were amplified
from cDNA isolated from the EBV-B cells of patients and controls,
with the 59-CAGAGGACGACTTTCAGCAC-39 and 59-CGCT-
GAGGATCACCATGCAG-39 primers. The amplicons were
inserted into pCR2.1 with the TA cloning kit (Invitrogen) and
sequenced with the same pair of primers. Sequences were
analyzed with Lasergene software (DNASTAR).
Mutagenesis of SLC29A3 construct and transfection of
HEK293T cells
WT variant 1 and variant 3 cDNA sequences were inserted into
the pcDNA3.1 vector with a V5 tag at the C-terminus by using the
pcDNA3.1/V5-His TOPO TA Expression kit from Invitrogen
(#K4800-01). WT variant 1 and variant 3 cDNA sequences were
inserted into pCMV6-XL4 vector (OriGene) with a Myc tag at the
N-terminus (BlueHeron). The c.243delA mutation was introduced
with the QuickChange site-directed mutagenesis kit from Strata-
gene (#200518). Primers for mutagenesis were synthesized by
Integrated DNA Technologies. For c.243delA, we used the
following primers: forward, 59- AGTACTGGATGTTCAACT-
CCGCAACTCC-39 and reverse, 59- GGAGTTGCGGAGTT-
GAACATCCAGTACT-39. Plasmids containing the WT or
mutated sequences were then amplified and purified with the
QIAprep Spin Miniprep Kit from Qiagen (#27106). The resulting
plasmids were used to transfect HEK293T cells in six-well plates,
using Lipofectamine LTX (Invitrogen, #15338-100).
Western blotting
Proteins were extracted 24 hours after transfection in lysis buffer
(50 nM TrisHCl, 150 mM NaCl, 1% NP-40, proteinase inhibi-
tors) for immunoblotting. Proteins were separated by electropho-
resis in a 9% acrylamide gel and blotted with, either a Myc-tag
antibody (Cell Signaling, #2272) or a V5-tag antibody (Invitrogen,
#R960CUS).
Mutant hENT3 cRNA expression in Xenopus oocytes and
measurement of transport activity
Xenopus oocyte expression constructs for hENT3-variant3-WT
were generated by PCR with the pOX-del36hENT3 (variant1-
WT) construct [18,31] as a template. We deleted the codons
corresponding to the first 36 amino acids of hENT3 from these
vectors, to target the protein to the cell surface to render the
experiment feasible, as previously described [18,28]. The HindIII
and XbaI restriction sites were used. The following primers were
used to amplify the insert from pCMV6-XL4-Myc-hENT3-
variant3-WT: forward, 59- CGATAAGCTTCAATAATGGAC-
CGCCCGCCCCCTGGCC-39 and reverse, 59- CGCGTCTA-
GACTAGATGAGGTGCACCAGGAGGGTAGA-39. The in-
serts were then released from the pOX-del36hENT3 vector by
cutting with HindIII and XbaI restriction enzymes (New England
Biolabs #R0104 and #R0145). Inserts and vectors were then
extracted from the gel and ligated together overnight, with T4
DNA ligase (New England Biolabs #M0202). We then used the
QuickChange site-directed mutagenesis kit from Stratagene
(#200518) to generate hENT3-variant1-81fs and hENT3-vari-
ant3-81fs. We used the following primers: forward, 59- AG-
TACTGGATGTTCAACTCCGCAACTCC-39 and reverse, 59-
GGAGTTGCGGAGTTGAACATCCAGTACT-39.
We generated cRNAs and carried out expression studies in
Xenopus oocytes as previously described [18,31]. We injected water
(control) or mutant-hENT3 cRNAs (200 ng/ml) into 80–100
defolliculated oocytes. We allowed expression of the mutant
constructs to occur over a 24-hour period and then incubated
viable oocytes with
3H-adenosine in a transport buffer containing
100 mM NaCl, 2 mM KCl, 1 mM CaCl2, 1 mM MgCl2, and
10 mM HEPES, pH 5.5. The rate of adenosine influx rates into
oocytes over a period of 30 minutes was then determined by liquid
scintillation counting and plotted.
Statistical analysis
Student’s t test was used to identify significant differences, and
experiments were repeated three times.
Supporting Information
Figure S1 Predicted model of hENT3-variant3-81fs.
Scheme of hENT3-variant3-81fs based on the protein structure
predicted by SVMtm or TMpred programs. Transmembrane
domains are represented by long rectangles.
(TIF)
Figure S2 hENT3-variant3-81fs leads to a stable protein
expression. Levels of hENT3 proteins were assessed by
immunoblotting with an anti-Myc-tag antibody. The Myc tag
was located at the N-terminus part of the protein. The
immunoblot is representative of three independent experiments.
(TIF)
Table S1 Variants identified by WES in the linked
intervals for P1.
(DOC)
Text S1 Predicted hENT3 WT and mutant sequences for
all variants. Alternate blue and black colors indicate the
different exons of the gene. Amino acids in red are encoded by
a codon overlapping two exons. A space was introduced each 10
amino acids for the sake of clarity.
(DOC)
Acknowledgments
We thank the patients and their family for their trust and collaboration. We
thank all members of the laboratories for helpful discussions. We thank Dr.
Pierre-Yves Lienhardt for clinical investigation of the patients. We thank
Drs. Alain Krivinsky, Regis Cohen, Philippe Caux, Robin Dhote and
Bertrand Wechsler for patient follow-up and detailed clinical information.
We thank Dr. Regis Tournebize and Dr. Philippe Sansonetti for expert
advice on the VCL mutation and for leading the rhinoscleroma project. We
thank Dr. Ekaitz Errasti-Murugarren, Dr. Isabel Huber-Ruano and Maya
Chrabieh for technical assistance and support.
Author Contributions
Conceived and designed the experiments: AB AP LA RG LDP JLC.
Performed the experiments: AB AA BP RY AP AG MB JFE. Analyzed the
data: AB AA MPA RG JFE LDP JLC. Wrote the paper: AB JLC.
Recruited the patients and performed the clinical investigation: DC JFE
LDP.
Hypomorphic Frameshift Deletion in SLC29A3
PLoS ONE | www.plosone.org 10 January 2012 | Volume 7 | Issue 1 | e29708References
1. de Pontual L, Ovetchkine P, Rodriguez D, Grant A, Puel A, et al. (2008)
Rhinoscleroma: a French national retrospective study of epidemiological and
clinical features. Clin Infect Dis 47: 1396–1402.
2. Boisson-Dupuis S, El Baghdadi J, Parvaneh N, Bousfiha A, Bustamante J, et al.
(2011) IL-12Rbeta1 deficiency in two of fifty children with severe tuberculosis
from Iran, Morocco, and Turkey. PLoS One 6: e18524.
3. Zhang SY, Jouanguy E, Ugolini S, Smahi A, Elain G, et al. (2007) TLR3
deficiency in patients with herpes simplex encephalitis. Science 317: 1522–1527.
4. von Bernuth H, Picard C, Jin Z, Pankla R, Xiao H, et al. (2008) Pyogenic
bacterial infections in humans with MyD88 deficiency. Science 321: 691–696.
5. Puel A, Cypowyj S, Bustamante J, Wright JF, Liu L, et al. (2011) Chronic
Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17
Immunity. Science 332: 65–68.
6. Liu L, Okada S, Kong XF, Kreins AY, Cypowyj S, et al. (2011) Gain-of-function
human STAT1 mutations impair IL-17 immunity and underlie chronic
mucocutaneous candidiasis. J Exp Med 208: 1635–1648.
7. Alcais A, Quintana-Murci L, Thaler DS, Schurr E, Abel L, et al. (2010) Life-
threatening infectious diseases of childhood: single-gene inborn errors of
immunity? Ann N Y Acad Sci 1214: 18–33.
8. Casanova JL, Abel L (2007) Primary immunodeficiencies: a field in its infancy.
Science 317: 617–619.
9. Ng SB, Buckingham KJ, Lee C, Bigham AW, Tabor HK, et al. (2010) Exome
sequencing identifies the cause of a mendelian disorder. Nat Genet 42: 30–35.
10. Byun M, Abhyankar A, Lelarge V, Plancoulaine S, Palanduz A, et al. (2010)
Whole-exome sequencing-based discovery of STIM1 deficiency in a child with
fatal classic Kaposi sarcoma. J Exp Med 207: 2307–2312.
11. Bolze A, Byun M, McDonald D, Morgan NV, Abhyankar A, et al. (2010)
Whole-exome-sequencing-based discovery of human FADD deficiency.
Am J Hum Genet 87: 873–881.
12. Walsh T, Shahin H, Elkan-Miller T, Lee MK, Thornton AM, et al. (2010)
Whole exome sequencing and homozygosity mapping identify mutation in the
cell polarity protein GPSM2 as the cause of nonsyndromic hearing loss
DFNB82. Am J Hum Genet 87: 90–94.
13. 1000 Genomes Project Consortium (2010) A map of human genome variation
from population-scale sequencing. Nature 467: 1061–1073.
14. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, et al. (2010)
A method and server for predicting damaging missense mutations. Nat Methods
7: 248–249.
15. Vasile VC, Ommen SR, Edwards WD, Ackerman MJ (2006) A missense
mutation in a ubiquitously expressed protein, vinculin, confers susceptibility to
hypertrophic cardiomyopathy. Biochem Biophys Res Commun 345: 998–1003.
16. Cliffe ST, Kramer JM, Hussain K, Robben JH, de Jong EK, et al. (2009)
SLC29A3 gene is mutated in pigmented hypertrichosis with insulin-dependent
diabetes mellitus syndrome and interacts with the insulin signaling pathway.
Hum Mol Genet 18: 2257–2265.
17. Doviner V, Maly A, Ne’eman Z, Qawasmi R, Aamar S, et al. (2010) H
syndrome: recently defined genodermatosis with distinct histologic features. A
morphological, histochemical, immunohistochemical, and ultrastructural study
of 10 cases. Am J Dermatopathol 32: 118–128.
18. Kang N, Jun AH, Bhutia YD, Kannan N, Unadkat JD, et al. (2010) Human
equilibrative nucleoside transporter-3 (hENT3) spectrum disorder mutations
impair nucleoside transport, protein localization, and stability. J Biol Chem 285:
28343–28352.
19. Molho-Pessach V, Lerer I, Abeliovich D, Agha Z, Abu Libdeh A, et al. (2008)
The H syndrome is caused by mutations in the nucleoside transporter hENT3.
Am J Hum Genet 83: 529–534.
20. Morgan NV, Morris MR, Cangul H, Gleeson D, Straatman-Iwanowska A, et al.
(2010) Mutations in SLC29A3, encoding an equilibrative nucleoside transporter
ENT3, cause a familial histiocytosis syndrome (Faisalabad histiocytosis) and
familial Rosai-Dorfman disease. PLoS Genet 6: e1000833.
21. Priya TP, Philip N, Molho-Pessach V, Busa T, Dalal A, et al. (2010) H
syndrome: novel and recurrent mutations in SLC29A3. Br J Dermatol 162:
1132–1134.
22. Spiegel R, Cliffe ST, Buckley MF, Crow YJ, Urquhart J, et al. (2010) Expanding
the clinical spectrum of SLC29A3 gene defects. Eur J Med Genet 53: 309–313.
23. Jonard L, Couloigner V, Pierrot S, Louha M, Gherbi S, et al. (2011) Progressive
hearing loss associated with a unique cervical node due to a homozygous
SLC29A3 mutation: A very mild phenotype. Eur J Med Genet;doi:10.1016/
j.ejmg.2011.06.009.
24. Bhuvanagiri M, Schlitter AM, Hentze MW, Kulozik AE (2010) NMD: RNA
biology meets human genetic medicine. Biochem J 430: 365–377.
25. Maquat LE (2004) Nonsense-mediated mRNA decay: splicing, translation and
mRNP dynamics. Nat Rev Mol Cell Biol 5: 89–99.
26. Sundaram M, Yao SY, Ingram JC, Berry ZA, Abidi F, et al. (2001) Topology of
a human equilibrative, nitrobenzylthioinosine (NBMPR)-sensitive nucleoside
transporter (hENT1) implicated in the cellular uptake of adenosine and anti-
cancer drugs. J Biol Chem 276: 45270–45275.
27. Baldwin SA, Beal PR, Yao SY, King AE, Cass CE, et al. (2004) The
equilibrative nucleoside transporter family, SLC29. Pflugers Arch 447: 735–743.
28. Baldwin SA, Yao SY, Hyde RJ, Ng AM, Foppolo S, et al. (2005) Functional
characterization of novel human and mouse equilibrative nucleoside transport-
ers (hENT3 and mENT3) located in intracellular membranes. J Biol Chem 280:
15880–15887.
29. Young JD, Yao SY, Sun L, Cass CE, Baldwin SA (2008) Human equilibrative
nucleoside transporter (ENT) family of nucleoside and nucleobase transporter
proteins. Xenobiotica 38: 995–1021.
30. Hyde RJ, Cass CE, Young JD, Baldwin SA (2001) The ENT family of eukaryote
nucleoside and nucleobase transporters: recent advances in the investigation of
structure/function relationships and the identification of novel isoforms. Mol
Membr Biol 18: 53–63.
31. Govindarajan R, Leung GP, Zhou M, Tse CM, Wang J, et al. (2009) Facilitated
mitochondrial import of antiviral and anticancer nucleoside drugs by human
equilibrative nucleoside transporter-3. Am J Physiol Gastrointest Liver Physiol
296: G910–922.
32. Avitan-Hersh E, Mandel H, Indelman M, Bar-Joseph G, Zlotogorski A, et al.
(2011) A case of H syndrome showing immunophenotye similarities to Rosai-
Dorfman disease. Am J Dermatopathol 33: 47–51.
33. Arnaud L, Hervier B, Neel A, Hamidou MA, Kahn JE, et al. (2011) CNS
involvement and treatment with interferon-alpha are independent prognostic
factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients.
Blood 117: 2778–2782.
34. Hansen KD, Lareau LF, Blanchette M, Green RE, Meng Q, et al. (2009)
Genome-wide identification of alternative splice forms down-regulated by
nonsense-mediated mRNA decay in Drosophila. PLoS Genet 5: e1000525.
35. Lewis BP, Green RE, Brenner SE (2003) Evidence for the widespread coupling
of alternative splicing and nonsense-mediated mRNA decay in humans. Proc
Natl Acad Sci USA 100: 189–192.
36. Abecasis GR, Cherny SS, Cookson WO, Cardon LR (2002) Merlin–rapid
analysis of dense genetic maps using sparse gene flow trees. Nat Genet 30:
97–101.
37. Li H, Durbin R (2009) Fast and accurate short read alignment with Burrows-
Wheeler transform. Bioinformatics 25: 1754–1760.
38. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, et al. (2010) The
Genome Analysis Toolkit: a MapReduce framework for analyzing next-
generation DNA sequencing data. Genome Res 20: 1297–1303.
39. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, et al. (2009) The Sequence
Alignment/Map format and SAMtools. Bioinformatics 25: 2078–2079.
Hypomorphic Frameshift Deletion in SLC29A3
PLoS ONE | www.plosone.org 11 January 2012 | Volume 7 | Issue 1 | e29708